BIOSCIENCE HEALTH INNOVATIONS INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.7M | $1.8M | $597.6K | $69.3K | $0 | $0 |
| Cost of Revenue | $2.4M | $536.1K | $113.2K | $9.7K | — | — |
| Gross Profit | $3.2M | $1.3M | $484.4K | $59.6K | — | — |
| Gross Margin | 57.0% | 70.9% | 81.1% | 86.0% | — | — |
| Operating Expenses | ||||||
| Research & Development | $161.4K | $25.9K | $0 | — | — | — |
| SG&A Expense | $2.2M | $1.1M | $706.3K | $151.3K | $25.6K | $7.7K |
| Operating Income | $719.1K | $87.0K | $-251.5K | $-170.5K | $-25.6K | $-7.7K |
| Operating Margin | 12.6% | 4.7% | -42.1% | -245.8% | — | — |
| Interest Expense | — | — | — | — | $450 | — |
| Pretax Income | — | — | — | $-83.2K | $-25.6K | — |
| Income Tax Expense | $77.0K | $0 | $0 | $0 | $0 | $0 |
| Net Income | $642.1K | $87.0K | $-251.5K | $-170.5K | $-25.6K | $-7.7K |
| Net Margin | 11.3% | 4.7% | -42.1% | -245.8% | — | — |
| EPS (Basic) | $0.06 | $0.01 | $-0.01 | — | $0.00 | $0.00 |
| EPS (Diluted) | $0.06 | $0.01 | $-0.01 | — | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 11.0M | 10.5M | 33.8M | 5.5M | 5.5M | 5.5M |
| Shares Outstanding (Diluted) | 11.4M | 10.9M | 33.8M | 5.5M | 5.5M | 5.5M |
| Dividends Per Share | — | — | — | — | — | — |